Methods, pharmaceutical compositions, and kits are provided for treating a subject with an effective amount of an oxytocin receptor (OXTR) agonist and an effective amount of an ALK5 antagonist. In certain aspects, the OXTR agonist may be oxytocin or an oxytocin analog (e.g., a small molecule). The ALK 5 antagonist may be a small molecule, such as 2-(3-(6-Methyl-pyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, LY2157299, A 83-01, D 4476, GW 788388, LY 364947, Rep Sox, SB 431542, SB 505124, SB 525334, or SD 208. In certain aspects, the amounts of the OXTR agonist and ALK5 antagonist may be sufficient to induce muscle regeneration and/or neural cell regeneration in the subject.

The present invention provides novel, long-acting nanoformulated drugs and targeted drug delivery methods, and uses thereof. In one embodiment, the nanoformulated drug is a retroviral drug. In one embodiment, the nanoformulated composition comprises a nanocarrier with one or more incorporated drugs. In an exemplary embodiment, the drug is efavirenz (EFV). In a further embodiment, the nanocarrier is associated with an agent for targeting microfold cells (M-cells). In a specific embodiment, the targeting agent binds to an M-cell marker known as glycoprotein 2 (GP2). Via this mechanism, the nanodrug is targeted toward GALT.

The present invention provides novel, long-acting nanoformulated drugs and targeted drug delivery methods, and uses thereof. In one embodiment, the nanoformulated drug is a retroviral drug. In one embodiment, the nanoformulated composition comprises a nanocarrier with one or more incorporated drugs. In an exemplary embodiment, the drug is efavirenz (EFV). In a further embodiment, the nanocarrier is associated with an agent for targeting microfold cells (M-cells). In a specific embodiment, the targeting agent binds to an M-cell marker known as glycoprotein 2 (GP2). Via this mechanism, the nanodrug is targeted toward GALT.

Etifoxine, or a pharmaceutically acceptable derivative thereof, can be used for the treatment of a disease related to activated mast cells in a subject, preferably a human. Furthermore, a pharmaceutical composition containing Etifoxine, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable excipient can be used for the treatment of a disease related to activated mast cells. An in vitro or ex-vivo method of inhibiting mast cell activation, involves contacting a cell with Etifoxine, or a pharmaceutically acceptable derivative thereof.

Etifoxine, or a pharmaceutically acceptable derivative thereof, can be used for the treatment of a disease related to activated mast cells in a subject, preferably a human. Furthermore, a pharmaceutical composition containing Etifoxine, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable excipient can be used for the treatment of a disease related to activated mast cells. An in vitro or ex-vivo method of inhibiting mast cell activation, involves contacting a cell with Etifoxine, or a pharmaceutically acceptable derivative thereof.

The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

The present invention relates to methods for the treatment of substance abuse disorder, dyspnea, tinnitus, child and adolescent depression, child and adolescent suicidal ideation and behavior, and child and adolescent anxiety using etifoxine or a pharmaceutically acceptable salt thereof.

The present invention relates to methods for the treatment of substance abuse disorder, dyspnea, tinnitus, child and adolescent depression, child and adolescent suicidal ideation and behavior, and child and adolescent anxiety using etifoxine or a pharmaceutically acceptable salt thereof.

The present invention relates to methods for the treatment of substance abuse disorder, dyspnea, tinnitus, child and adolescent depression, child and adolescent suicidal ideation and behavior, and child and adolescent anxiety using etifoxine or a pharmaceutically acceptable salt thereof.